Rhee YH, Ku HJ, Noh HJ, Cho HH, Kim HK, Ahn JC. Anti-Helicobacter pylori effect of CaG-NANA, a new sialic acid derivative. World J Gastrointest Pathophysiol 2016; 7(4): 300-306 [PMID: 27895975 DOI: 10.4291/wjgp.v7.i4.300]
Corresponding Author of This Article
Jin-Chul Ahn, MD, Department of Biomedical Science, College of Medicine, Dankook University, 119 Dandae-ro, Cheonan, Chungnam 31116, South Korea. jcahn@dankook.ac.kr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pathophysiol. Nov 15, 2016; 7(4): 300-306 Published online Nov 15, 2016. doi: 10.4291/wjgp.v7.i4.300
Anti-Helicobacter pylori effect of CaG-NANA, a new sialic acid derivative
Yun-Hee Rhee, Hyun-Jeong Ku, Hye-Ji Noh, Hyang-Hyun Cho, Hee-Kyong Kim, Jin-Chul Ahn
Yun-Hee Rhee, Hyun-Jeong Ku, Jin-Chul Ahn, Beckman Laser Institute Korea, Dankook University, Chungnam 31116, South Korea
Hye-Ji Noh, Hyang-Hyun Cho, Hee-Kyong Kim, MEDINUTROL Co., Jeonnam 57024, South Korea
Jin-Chul Ahn, Department of Biomedical Science, College of Medicine, Dankook University, Chungnam 31116, South Korea
Jin-Chul Ahn, Medical Laser Research Center, Dankook University, Chungnam 31116, South Korea
Author contributions: Rhee YH performed the majority of experiments, analyzed the data, and wrote the manuscript; Ku HJ and Noh HJ participated in animal experiments; Cho HH, Kim HK and Ahn JC designed and coordinated the research.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Dankook University (IACUC protocol number: DKU-14-036).
Conflict-of-interest statement: The authors have no conflict of interest to declare.
Data sharing statement: Statistics and histology analysis of data are available from the corresponding author at jcahn@dankook.ac.kr.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jin-Chul Ahn, MD, Department of Biomedical Science, College of Medicine, Dankook University, 119 Dandae-ro, Cheonan, Chungnam 31116, South Korea. jcahn@dankook.ac.kr
Telephone: +82-1899-3700
Received: June 28, 2016 Peer-review started: June 29, 2016 First decision: August 10, 2016 Revised: August 12, 2016 Accepted: September 13, 2016 Article in press: September 18, 2016 Published online: November 15, 2016 Processing time: 138 Days and 2.8 Hours
Abstract
AIM
To investigate the bactericidal effects of calcium chelated N-acetylneuraminic acid-glycomacropeptide (CaG-NANA) against Helicobacter pylori (H. pylori).
METHODS
For manufacture of CaG-NANA, calcium (Ca) was combined with glycomacropeptide (GMP) by chelating, and N-acetylneuraminic acid (NANA) was produced with Ca-GMP substrate by an enzymatic method. The final concentration of each component was 5% Ca, 7% NANA, 85% GMP, and 3% water. For in vitro study, various concentrations of CaG-NANA were investigated under the minimal inhibitory concentration (MIC). For in vivo study, CaG-NANA was administered orally for 3 wk after H. pylori infection. The levels of inflammatory cytokines in blood were analyzed by enzyme-linked immunosorbent assay and eradication of H. pylori was assessed by histological observation.
RESULTS
The time-kill curves showed a persistent decrease in cell numbers, which depended on the dose of CaG-NANA, and MIC of CaG-NANA against H. pylori was 0.5% in vitro. Histopathologic observation revealed no obvious inflammation or pathologic changes in the gastric mucosa in the CaG-NANA treatment group in vivo. The colonization of H. pylori was reduced after CaG-NANA treatment. The levels of interleukin (IL)-6, IL-1β, tumor necrosis factor-α, and IL-10 were also decreased by CaG-NANA.
CONCLUSION
CaG-NANA demonstrates effective anti-bactericidal activity against H. pylori both in vitro and in vivo.
Core tip: Calcium chelated N-acetylneuraminic acid-glycomacropeptide demonstrates effective anti-bactericidal activity against Helicobacter pylori both in vitro and in vivo.
